Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CroatiaBack to Croatia

Clinical trials in Zagreb – page 10

257 clinical trials in Zagreb, Croatia across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Zagreb at a glance
257
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

257 trials in Zagreb

Open in trial search

Factor VIII deficiency+1

Not yet recruiting

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study on the Effects and Safety of Guselkumab for Patients with Active Psoriatic Arthritis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Hidradenitis

Not recruiting

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Zagreb

What the registry says about research in the country

01 Autoimmune Conditions

Clinical investigations focusing on autoimmune disorders encompass treatments for psoriatic arthritis, Sjögren's Syndrome, and systemic lupus erythematosus, evaluating novel therapeutic approaches for improved patient outcomes.

  • Psoriatic Arthritis Studies
  • Sjögren's Syndrome Research
  • Lupus Treatment Trials

These trials aim to assess new biological medicines and their effectiveness in managing chronic inflammatory conditions.

02 Neurological Disorders

Research initiatives targeting neurological conditions focus on multiple sclerosis and Alzheimer's disease-related psychosis, exploring innovative treatment approaches for better disease management.

  • Multiple Sclerosis Therapies
  • Alzheimer's-Related Psychosis
  • Neurological Disease Management

Studies evaluate both established and emerging treatments to improve patient outcomes and quality of life.

03 Oncology Research

Advanced cancer research programs examine treatments for lung cancer, leukemia, and thyroid cancer, investigating targeted therapies and combination treatments.

  • Non-Small Cell Lung Cancer
  • Acute Lymphoblastic Leukemia
  • Medullary Thyroid Cancer

These trials focus on improving survival rates and developing more effective treatment strategies.

Back to CroatiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.